Redaporfin (Synonyms: LUZ11; F2BMet) |
| Catalog No.GC62293 |
Redaporfin(LUZ11)은 강력한 감광제로 작용합니다. Redaporfin은 직접적인 항종양 효과뿐만 아니라 악성 병변의 간접적인 면역 의존적 파괴를 일으킵니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1224104-08-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Redaporfin (LUZ11) acts as a potent photosensitizer. Redaporfin causes direct antineoplastic effects as well as indirect immune‐dependent destruction of malignant lesions[1].
The combination photodynamic therapy (PDT) with Redaporfin (5μM) induces a reduction in the abundance of several Golgi apparatus (GA) proteins such as Golgi brefeldin A-resistant guanine nucleotide exchange factor 1 (GBF1), golgin subfamily A member 2 (GOLGA2), and galactosyltransferase 1 (GALT1), as well as that of two ER proteins, eukaryotic translation initiation factor 2-alpha (eIF2α) kinase 3 (EIF2AK3) and protein disulfide-isomerase A3 (PDIA3). In contrast, there is no major decrease in mitochondrial import receptor subunit TOM20 homolog (TOMM20) or in the cytoskeleton protein β-actin[1].
[1]. LÍgia C Gomes-da-Silva, et al. Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus. EMBO J. 2018 Jul 2;37(13):e98354.
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *